Clinical Trial Update: Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma [Phase 2]

View source ↗

Summary

A Phase 2 trial of brentuximab vedotin in classical Hodgkin lymphoma was terminated, with results posted in December 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hodgkin Lymphoma

Drugs mentioned

• Brentuximab vedotin (Brentuximab vedotin)

Snippet

Sponsor: Seagen Inc. | Conditions: Hodgkin Lymphoma | Phase 2 | Status: TERMINATED | Results posted: 2023-12-21